SCHEMBL4488042

SCHEMBL4488042

CN(C(=O)c1ccc(O)cc1)C1CCCCC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.59
GAA P10253 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
POLB P06746 2/20 0.58
NPC1 O15118 2/20 0.58
RAB9A P51151 2/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
HPGD P15428 2/20 0.53
TSHR P16473 1/20 0.53
LMNA P02545 2/20 0.51
MAPT P10636 1/20 0.51
CNR2 P34972 1/20 0.50
PTAFR P25105 1/20 0.48
KDM4E B2RXH2 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
RECQL P46063 1/20 0.47
ADAM17 P78536 1/20 0.47
MAPK14 Q16539 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9001766 0.93 ALDH1A1 (0.66) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL8130980 0.86 POLB (0.62) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL95169 0.85 ALDH1A1 (0.58) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL3455662 0.85 KCNH2 (0.63) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL3455371 0.85 ALDH1A1 (0.58) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL20460603 0.85 ALDH1A1 (0.58) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL20460529 0.84 POLB (0.60) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL14374144 0.84 HPGD (0.62) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL1001922 0.84 HPGD (0.62) ALDH1A1GAASMN1; SMN2POLBNPC1
SCHEMBL13712766 0.83 ALDH1A1 (0.57) ALDH1A1GAASMN1; SMN2POLBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101230033-B New azabicycloalkane derivatives, preparing method and medicament combination containing the same SERVIER LAB 2011-03-09 CN disclosed
CN-100577160-C Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same SERVIER LAB 2010-01-06 CN disclosed
US-7576120-B2 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2009-08-18 US disclosed
CN-101230033-A New azabicycloalkane derivatives, preparing method and medicament combination containing the same SERVIER LAB (FR) 2008-07-30 CN disclosed
EP-1720544-B1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2008-03-19 EP disclosed
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. LES LABORATORATIES SERVIER (FR) 2007-08-23 US disclosed
CN-1921848-A Novel azabicyclo derivatives, preparation method thereof and pharmaceutical compositions containing same SERVIER LAB (FR) 2007-02-28 CN disclosed
EP-1720544-A1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier (FR) 2006-11-15 EP disclosed
WO-2005089747-A1 NOVEL AZABICYCLIC DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME LES LABORATOIRES SERVIER (FR) 2005-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197625-A1 Azabicyclic compounds, a process for their preparation and pharmaceutical compositions containing them. HRH2, HNMT, HRH1 ALDH1A1 308/4885GAA 738/4885SMN1; SMN2 855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.